Psilocybin is a single tryptamine molecule, and it is not quite the thing that acts on your brain. It is a prodrug: after ingestion it is rapidly converted to psilocin, and psilocin is what crosses into the brain and binds the serotonin 5-HT2A receptor. [1] Peer-reviewed Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man doi:10.1016/s0031-6865(97)00014-9 [2] Peer-reviewed Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance doi:10.1080/03602532.2016.1278228 Its subjective effects track plasma psilocin and receptor occupancy, measured at full perceptual doses. [3] Peer-reviewed Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels doi:10.1038/s41386-019-0324-9 It is the most-studied microdosing substance — comparatively well characterised, shorter-acting than LSD, and the one most surveys report — but “most-studied” is relative, and almost all of its pharmacology comes from full doses, not microdoses. A substance being studied at full dose is not the same as it being studied at a microdose, and knowing what psilocybin is does not establish what a microdose of it does.
This is an education-only research review, not sourcing, dosing, medical, or legal advice. It describes the psilocybin molecule and what research has measured. It is not a guide to obtaining, preparing, or dosing anything. The mushroom material is covered in the mushroom-intelligence cluster, dosing in protocols, and risk in safety. For personal decisions, consult a qualified clinician.
The molecule, not the mushroom
The first distinction worth making is between psilocybin the compound and the mushroom that contains it. Psilocybin is 4-phosphoryloxy-N,N-dimethyltryptamine — a defined chemical. A mushroom is biological material in which psilocybin coexists with psilocin and several minor tryptamines such as baeocystin and norpsilocin, in proportions that vary by species, specimen, and storage. [4] Peer-reviewed Synthesis and Biological Evaluation of Tryptamines Found in Hallucinogenic Mushrooms: Norbaeocystin, Baeocystin, Norpsilocin, and Aeruginascin doi:10.1021/acs.jnatprod.9b01061 This page is about the molecule; the material, its species, and why its potency is uncertain belong to the mushroom-intelligence cluster.
The practical consequence of the distinction is precision. A milligram of pure psilocybin is a known quantity; a fraction of a gram of dried mushroom is not, because the psilocybin content of that material is variable. Much confusion about “doses” dissolves once the compound and the material are kept apart. Natural origin does not make a substance chemically standardised: fungi and the preparations made from them vary in active-compound content, in the accompanying compounds present, and in how they degrade over time. So evidence from purified psilocybin cannot be treated as identical to evidence from untested mushroom material — they are different inputs even when the active molecule is the same.
A prodrug for psilocin
Psilocybin itself is largely a delivery form. After oral intake it is rapidly dephosphorylated to psilocin, the pharmacologically active species, which is what enters the brain and acts at 5-HT2A receptors. [1] Peer-reviewed Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man doi:10.1016/s0031-6865(97)00014-9 [2] Peer-reviewed Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance doi:10.1080/03602532.2016.1278228 In human pharmacokinetic work, plasma psilocin rises and falls over a few hours, and oral psilocybin is well absorbed with measurable inter-individual variability. [5] Peer-reviewed Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults doi:10.1007/s40262-017-0540-6 When research describes “psilocybin in the brain,” it is really describing psilocin.
This conversion step is why statements about psilocybin and psilocin are not interchangeable, and why the pharmacokinetics page in How It Works treats the conversion, distribution, and elimination in detail. Psilocin is further metabolised and cleared, with renal excretion characterised in controlled human study. [2] Peer-reviewed Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance doi:10.1080/03602532.2016.1278228
| Psilocybin | Psilocin | |
|---|---|---|
| Role | Prodrug (delivery form) | Active compound |
| Acts at 5-HT2A directly | No (converted first) | Yes |
| What effects track | — | Plasma psilocin and receptor occupancy |
| Stability | More stable | More prone to oxidation |
Why effects track psilocin, not the nominal dose
A notable human imaging study found that the subjective intensity of psilocybin’s effects correlated with 5-HT2A receptor occupancy and with plasma psilocin levels, rather than with the nominal dose alone. [3] Peer-reviewed Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels doi:10.1038/s41386-019-0324-9 In other words, what a person experiences maps onto how much psilocin reaches and occupies the receptor — a quantity shaped by conversion, absorption, and individual physiology. This is mechanistic detail measured at perceptual doses; it describes how the compound behaves, not whether a sub-perceptual amount produces a benefit.
Why psilocybin is the most-studied microdosing substance
Several factors make psilocybin the default subject of microdosing research and surveys: its pharmacology is comparatively well mapped among psychedelics, [6] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478 its duration is shorter than LSD’s, and mushrooms are the material most reported by the cohorts studied. But “most-studied microdosing substance” is a low bar in absolute terms. The microdosing literature remains dominated by uncontrolled self-report, and the well-characterised pharmacology above comes from full perceptual doses in clinical settings — not from sub-perceptual repeated dosing. Psilocybin is the most directly represented substance in microdosing research, but “most studied” is not the same as “demonstrated effective”; it means the evidence base is less empty here than elsewhere, not that the question is settled.
| Better characterised (full-dose / lab) | Open for microdosing |
|---|---|
| Prodrug conversion to psilocin | Whether sub-perceptual doses produce measurable benefit |
| Plasma psilocin time course | Long-term repeated low-dose effects |
| 5-HT2A occupancy at perceptual doses | Dose-response below the perceptual threshold |
| Acute physiological profile | Cumulative pharmacology of frequent dosing |
Holding the distinctions
Everything above is identity and pharmacology, not outcome. Mechanism is not result: psilocin occupying 5-HT2A is a pathway, not a demonstrated microdosing benefit. Full-dose is not microdose: the occupancy and dose-effect data come from perceptual doses and do not transfer downward. And the compound is not the mushroom: a precise statement about the molecule says nothing about the variable material people actually take. For how the receptor mechanism plays out, see the 5-HT2A mechanism; for why the material’s potency is uncertain, potency variability; for what the low-dose evidence actually covers, what the research covers; and for the physiological profile, the safety cluster.
- Prodrug → active
- Psilocybin converts to psilocin, which is the species that acts at 5-HT2A; effects track psilocin. [1] Peer-reviewed Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man doi:10.1016/s0031-6865(97)00014-9
- Compound ≠ material
- Pure psilocybin is a precise quantity; mushroom material containing it is variable. [4] Peer-reviewed Synthesis and Biological Evaluation of Tryptamines Found in Hallucinogenic Mushrooms: Norbaeocystin, Baeocystin, Norpsilocin, and Aeruginascin doi:10.1021/acs.jnatprod.9b01061
- Occupancy at perceptual doses
- Effect intensity correlates with 5-HT2A occupancy and plasma psilocin — measured at full doses. [3] Peer-reviewed Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels doi:10.1038/s41386-019-0324-9
- Most-studied ≠ well-studied at a microdose
- Psilocybin leads the microdosing literature, which is itself thin and self-report-dominated.
Frequently asked questions
Is psilocybin the same thing as a magic mushroom?
No. Psilocybin is a single molecule; a mushroom is biological material that contains psilocybin alongside psilocin, baeocystin, and other compounds in variable amounts. [4] Peer-reviewed Synthesis and Biological Evaluation of Tryptamines Found in Hallucinogenic Mushrooms: Norbaeocystin, Baeocystin, Norpsilocin, and Aeruginascin doi:10.1021/acs.jnatprod.9b01061 This page is about the molecule — its structure, how the body converts it, and what research has measured. The mushroom as material — which species contain it, how potency varies, how it degrades — is a separate subject covered in the mushroom-intelligence cluster. Treating the compound and the mushroom as identical is a common source of confusion, because a fixed dose of pure psilocybin is precise while a fixed weight of mushroom is not.
What does it mean that psilocybin is a prodrug?
A prodrug is an inactive or less-active compound that the body converts into the active one. Psilocybin is rapidly dephosphorylated after ingestion into psilocin, and it is psilocin that crosses into the brain and acts at serotonin 5-HT2A receptors. [1] Peer-reviewed Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man doi:10.1016/s0031-6865(97)00014-9 [2] Peer-reviewed Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance doi:10.1080/03602532.2016.1278228 In studies, the subjective effects track plasma psilocin, not psilocybin itself. [3] Peer-reviewed Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels doi:10.1038/s41386-019-0324-9 This matters for reading claims: statements about “psilocybin in the brain” are really about psilocin, and the conversion step is one reason oral timing and individual variation exist.
Why is psilocybin the most-studied microdosing substance?
Several reasons converge: its pharmacology is comparatively well characterised, [6] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478 it has a shorter duration than LSD, it is the substance most surveys and citizen-science cohorts report using, and mushrooms are widely available in the populations studied. But “most studied” is relative — the microdosing evidence is still thin and dominated by uncontrolled self-report, and most of what is known about psilocybin pharmacology comes from full perceptual doses, not microdoses. Being the best-studied microdosing substance is not the same as being well-studied at a microdose.
Does knowing psilocybin's pharmacology tell me if microdosing works?
No. Pharmacology describes what the molecule does to receptors and how the body handles it; it does not establish that a sub-perceptual dose produces any particular benefit. The receptor occupancy and dose-effect data come from perceptual doses, [3] Peer-reviewed Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels doi:10.1038/s41386-019-0324-9 and a plausible mechanism is not a demonstrated outcome. Whether repeated microdoses of psilocybin do anything beyond expectation is an empirical question the pharmacology cannot answer on its own — that is the mechanism-is-not-result distinction the whole site holds.
Is psilocybin the same thing as a mushroom dose?
No. Psilocybin is a molecule. A mushroom amount is a weight of biological material whose psilocybin and psilocin content can vary by species, specimen, and storage. [4] Peer-reviewed Synthesis and Biological Evaluation of Tryptamines Found in Hallucinogenic Mushrooms: Norbaeocystin, Baeocystin, Norpsilocin, and Aeruginascin doi:10.1021/acs.jnatprod.9b01061 A stated quantity of pure psilocybin is precise; a stated weight of mushroom is not, because what is inside that weight varies. This is why evidence gathered with purified, measured psilocybin cannot be treated as identical to the experience of an unmeasured amount of mushroom material.